- In January 2024, Tarsier Pharma, Ltd., a clinical-stage ophthalmic biopharmaceutical company, has received FDA approval under a Special Protocol Assessment (SPA) for the clinical trial protocol and statistical analysis of the Tarsier-04 Phase 3 trial, evaluating TRS01 eye drops for non-infectious uveitis, including uveitic glaucoma. This approval paves the way for advancing TRS01 towards potential commercialization, strengthening the company’s position in the ophthalmic market
- In February 2019, EyePoint Pharmaceuticals, Inc. has officially launched YUTIQTM in the U.S., a three-year micro-insert FDA-approved for treating chronic non-infectious uveitis affecting the posterior segment of the eye. This launch enhances the company’s portfolio, positioning it as a leader in long-term ophthalmic treatments and expanding its market presence.
